Our first objective was to validate the previous findings that ZNF154 and ZNF132 were epigenetically silenced in HNSCC tumors, and to test whether their expression might be prognostically relevant in this disease. This evidence concerns the gene ZNF132 and head and neck squamous cell carcinoma.